Convalescent Plasma to Stem Coronavirus (CSSC-001)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
Epistemonikos ID: afd074467a350176c2489371aec17d002f1d2e4c
First added on: Mar 31, 2020